(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 September 2005 (01.09.2005)

PCT

(10) International Publication Number
WO 2005/080373 A1

(51) International Patent Classification[7]: C07D 401/12, 215/48, A61K 31/47, 31/4709, A61P 3/04, 9/10

(21) International Application Number: PCT/IB2005/000167

(22) International Filing Date: 24 January 2005 (24.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/541,678 4 February 2004 (04.02.2004) US
60/633,763 6 December 2004 (06.12.2004) US

(71) Applicant *(for all designated States except US)*: **PFIZER PRODUCTS INC.** [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BERTINATO, Peter** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **COUTURIER, Michel, Andre** [CA/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **HAMANAKA, Ernest, Seiichi** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **EWING, Marcus, Douglas** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **ROBINSON, Ralph, Pelton, Jr.** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **TICKNER, Derek, Lawrence** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US).

(74) Agents: **FULLER, Grover, F, Jr.** et al.; C/O LAWRENCE, Jackie, Pfizer Inc. MS8260-1615, Eastern Point Road, Groton, CT 06340 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/080373 A1

(54) Title: SUBSTITUTED QUINOLINE COMPOUNDS



(I)

(57) Abstract: This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R^1-R^7, X^1, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.